Tempus AI stock crashed Tuesday as investors questioned the medical AI company's long-term growth prospects. But William Blair analyst Andrew Brackmann remains a believer in the stock. Tempus uses ...

Tempus AI is seeing strong growth as companies remain interested in the AI industry. Its annual revenue has jumped from $62.1 million in 2019 to over $531 million in the last financial year.

Deep 6 is integrated with over 750 provider site locations spanning more than 30 million patients, which will materially add to Tempus’ existing network CHICAGO, March 11, 2025--(BUSINESS WIRE ...

Tempus AI, Inc. TEM recently announced the acquisition of Deep 6 AI, a leading artificial intelligence (AI) company specializing in clinical trial matching. This strategic move aims to enhance ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen its stock perform exceptionally well this year. Investors have found the ...

Shares of Tempus AI (NASDAQ:TEM) dropped 19% Tuesday, the day after the AI-focused healthcare company released a Q4 earnings report that missed Street estimates and its 2025 financial forecast.

Investing.com -- JP Morgan downgraded Tempus AI to Neutral from Overweight given concerns over stock’s valuation after a sharp stock rally which was driven by the company’s solid fourth ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company Tempus AI (TEM). Yet, over the past five days, the stock has lost ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the ...

Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, reflecting confidence in the growth potential of the tech company that ...